GLP-1 Drug Shortages and Compounding July 2024 IPD has released a new podcast episode, GLP-1 Drug Shortages and Compounding," where Alyssa Guest, PharmD, discusses the glucagon-like peptide-1 (GLP-1) drugs and how interest in weight loss, viral social media posts, celebrity endorsements, illegitimate compounding, and drug shortages have all impacted access to GLP-1s
Shen X, Wang G, He H, Shang P, Yan B, Wang X, et al
The LEADER, REWIND, and SUSTAIN-6 trials of respective liraglutide 1.8 mg/daily (or maximum tolerated dose), once-weekly dulaglutide 1.5 mg, and once-weekly semaglutide 0.5 mg or 1.0 mg administration in patients with type 2 diabetes and cardiovascular disease or risk factors found decreased hazard ratios ranging from 0.74 to 0.88 for the primary composite endpoint first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke [112114]
Intrinsic electrical properties of mammalian neurons and CNS function: a historical perspective
Key Takeaways: Liposomal glutathione reaches your cells with up to 8090% bioavailability, far higher than that of standard oral tablets, which are under 20%
If you are still figuring out what fits best, our Cymbiotika Expert health quiz is a natural next step
